| DC Field | Value | Language |
|---|
| dc.contributor.author | Lupaşco, Iulianna | |
| dc.contributor.author | Dumbrava, Vlada-Tatiana | |
| dc.date.accessioned | 2019-09-20T09:22:56Z | |
| dc.date.available | 2019-09-20T09:22:56Z | |
| dc.date.issued | 2016 | |
| dc.identifier.citation | LUPAŞCO, Iulianna, DUMBRAVA, Vlada-Tatiana. Tratamentul antiviral al pacienţilor cu hepatită cronică C (eficienţa și monitorizarea). In: Sănătate Publică, Economie şi Management în Medicină. 2016, nr. 4(68), pp. 69-73. ISSN 1729-8687. | en_US |
| dc.identifier.issn | 1729-8687 | |
| dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/6781 | |
| dc.identifier.uri | http://revistaspemm.md/wp-content/uploads/2019/05/cm4_68_2016cf.pdf | |
| dc.description | USMF Nicolae Testemițanu, Laboratorul Gastroenterologie, Conferința naţională de gastroenterologie şi hepatologie cu participare internaţională ”Actualităţi în gastroenterologie şi hepatologie” 16 iunie 2016 Chișinău, Republica Moldova | en_US |
| dc.description.abstract | Republic of Moldova is keeping a leader place in Europe in terms of the prevalence of chronic hepatitis C, early treatment of which can prevent progression ij liver cirrhosis. All of 54 HCV patients who received combination antiviral therapy with PEG IFN α2β + Ribavirin where closely followed up. Aviremia (negative ARN HCV) with sustained viral response (SVR) achieved in 70,83% of cases. Monitoring of clinical and biochemical parameters of patients with SVR showed diminishing values of ALT, AST, GGTP, but not to the normal values of the control group. In patients with a lack of ARN HCV and achieved SVR at 48-72 weeks of follow up were found abnormal indices of IgM, IgG, circulating immune complexes (CIC), indicating the persistence of immune disorders in chronic hepatitis HCV. During this period of observation of patients with chronic hepatitis HCV a thyroid dysfunction was found with an increase of thyroid stimulating hormone (TSH) level and titer of antibodies to thyroid peroxidase (anti-TPO). | en_US |
| dc.description.abstract | Республика Молдова занимает ведущее место в Европе по распространенности ХГС, своевременное лечение которого предупреждает прогрессирование в ЦП. Обследовано 54 больных ХГС, получивших комбинированное лечение ПЕГ ИНФ α2β + рибавирин. Авиремия (РНК HCV негативная) с наличием устойчивого вирусного ответа (УВО) достигнута в 70,83% случаев. Мониторинг клинико-биохимических параметров у лиц с УВО выявил снижение активности АЛТ, АСТ, ГГТП, однако не до значений в группе контроля. У пациентов с отсутствием вируса гепатита С и УВО на 48-72 неделях наблюдения не отмечено нормализация IgM, IgG, ЦИК, что свидетельствует о персистенции иммунных нарушений при ХГС. В эти сроки наблюдения больных при ХГС сохраняется и нарушение функции щитовидной железы, увеличение тиреотропного гормона (ТТГ) и титра антител к тиреоидной пероксидазе (анти-ТПО). | |
| dc.language.iso | ro | en_US |
| dc.publisher | Asociația Obștească ”Economie, Management și Psihologie în Medicină” din Republica Moldova | en_US |
| dc.subject | chronic viral hepatitis C | en_US |
| dc.subject | treatment | en_US |
| dc.subject | PEG Interferon α2β | en_US |
| dc.subject.mesh | Hepatitis, Chronic--drug therapy | en_US |
| dc.subject.mesh | Interferon alpha-2--therapeutic use | en_US |
| dc.subject.mesh | Ribavirin--therapeutic use | en_US |
| dc.subject.mesh | Ursodeoxycholic Acid--therapeutic use | en_US |
| dc.subject.mesh | Drug Therapy, Combination | en_US |
| dc.title | Tratamentul antiviral al pacienţilor cu hepatită cronică C (eficienţa și monitorizarea) | en_US |
| dc.title.alternative | Antiviral treatment of patients with chronic hepatitis C (the effi ciency and monitoring) | en_US |
| dc.title.alternative | Антивирусное лечение больных хроническим гепатитом С (эффективность и мониторинг) | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Sănătate Publică, Economie şi Management în Medicină Nr. 4 (68) / 2016
|
